Showing results (101-110 of 125) with videos related to

Sort By:
Pageof 13
Journal of Medicinal Chemistry|January 18, 2022
Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of MTAP-Deleted CancersChristopher R Smith, Ruth Aranda, Thomas P Bobinski, et al.
Cancer Research|July 28, 2011
A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitorsTakaaki Sasaki, Jussi Koivunen, Atsuko Ogino, et al.
The New England Journal of Medicine|June 3, 2022
Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRAS MutationPasi A Jänne, Gregory J Riely, Shirish M Gadgeel, et al.
Cancer Discovery|December 6, 2022
Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic CancerSamantha B Kemp, Noah Cheng, Nune Markosyan, et al.
Science Signaling|November 13, 2014
Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFRPeter J Belmont, Ping Jiang, Trevor D McKee, et al.
Journal of Medicinal Chemistry|July 14, 2022
Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein-Protein InteractionJohn M Ketcham, Jacob Haling, Shilpi Khare, et al.
The New England Journal of Medicine|September 30, 2014
Crizotinib in ROS1-rearranged non-small-cell lung cancerAlice T Shaw, Sai-Hong I Ou, Yung-Jue Bang, et al.
Cancer Research|September 20, 2023
Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor EfficacySuman Mukhopadhyay, Hsin-Yi Huang, Ziyan Lin, et al.
Cancer Research|July 22, 2025
Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic CancerKristina Drizyte-Miller, Lars D Engstrom, Jeffrey A Klomp, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2017
Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical ModelsLars D Engstrom, Ruth Aranda, Matthew Lee, et al.
Pageof 13